Emerging Therapies for Multiple Myeloma
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 1915
Special Issue Editor
Special Issue Information
Dear Colleagues,
Multiple myeloma (MM) is a complex hematological malignancy. The treatment of multiple myeloma has evolved rapidly in recent years with the emergence of many new drugs and new data from randomized trials. These research frontiers have brought new hope for the treatment of multiple myeloma.
This Special Issue focuses on the latest advances and trends in the treatment of multiple myeloma. We hope to contribute to a comprehensive understanding of multiple myeloma treatment by providing insight into the rationale, clinical trial results, and potential applications of emerging therapeutic approaches. The scope of this Special Issue covers a variety of emerging treatment methods, including but not limited to targeted therapy, immunotherapy, CAR-T cell therapy, new drugs, and personalized medicine.
We invite researchers in the field of multiple myeloma-related areas to submit their findings as original articles or reviews to this Special Issue.
Dr. Brea C. Lipe
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- immunotherapy
- targeted therapy
- CAR-T cell therapy
- new drugs
- transplant
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
